GB201819430D0 - Therapeutic compounds, nanoparticles and uses thereof - Google Patents

Therapeutic compounds, nanoparticles and uses thereof

Info

Publication number
GB201819430D0
GB201819430D0 GBGB1819430.8A GB201819430A GB201819430D0 GB 201819430 D0 GB201819430 D0 GB 201819430D0 GB 201819430 A GB201819430 A GB 201819430A GB 201819430 D0 GB201819430 D0 GB 201819430D0
Authority
GB
United Kingdom
Prior art keywords
nanoparticles
therapeutic compounds
therapeutic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1819430.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Midatech Ltd
Original Assignee
Midatech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midatech Ltd filed Critical Midatech Ltd
Priority to GBGB1819430.8A priority Critical patent/GB201819430D0/en
Publication of GB201819430D0 publication Critical patent/GB201819430D0/en
Priority to PCT/EP2019/082810 priority patent/WO2020109428A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1819430.8A 2018-11-29 2018-11-29 Therapeutic compounds, nanoparticles and uses thereof Ceased GB201819430D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1819430.8A GB201819430D0 (en) 2018-11-29 2018-11-29 Therapeutic compounds, nanoparticles and uses thereof
PCT/EP2019/082810 WO2020109428A1 (fr) 2018-11-29 2019-11-27 Composés thérapeutiques, nanoparticules et leurs utilisations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1819430.8A GB201819430D0 (en) 2018-11-29 2018-11-29 Therapeutic compounds, nanoparticles and uses thereof

Publications (1)

Publication Number Publication Date
GB201819430D0 true GB201819430D0 (en) 2019-01-16

Family

ID=65024711

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1819430.8A Ceased GB201819430D0 (en) 2018-11-29 2018-11-29 Therapeutic compounds, nanoparticles and uses thereof

Country Status (2)

Country Link
GB (1) GB201819430D0 (fr)
WO (1) WO2020109428A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591386B (zh) * 2022-05-10 2022-09-09 深圳厚存纳米药业有限公司 一种含尿苷衍生物的纳米粒、核酸纳米复合物及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
US6913748B2 (en) 2002-08-16 2005-07-05 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
GB0313259D0 (en) 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
ES2242528B1 (es) 2004-03-25 2006-12-01 Consejo Sup. Investig. Cientificas Nanoparticulas magneticas de metales nobles.
EP2330208B1 (fr) 2004-05-24 2017-10-18 Midatech Ltd. Nanoparticules portant des ligands ARN
CA2582668C (fr) 2004-10-01 2013-10-01 Midatech Ltd Nanoparticules comprenant des antigenes et des adjuvants et structures immunogenes
CA2617869C (fr) 2005-08-04 2017-02-14 Thomas William Rademacher Nanoparticules comprenant des ligands antibacteriens
ATE517613T1 (de) 2006-04-13 2011-08-15 Midatech Ltd Nanoteilchen mit drei verschiedenen liganden zur auslösung einer immunantwort gegen infektiöse mittel
KR101105428B1 (ko) 2009-02-12 2012-01-17 경북대학교 산학협력단 글리피칸-3 단백질과 특이적으로 결합하는 펩타이드
WO2011048503A2 (fr) 2009-10-22 2011-04-28 Moro Ricardo J Peptides qui se lient au récepteur de l'alpha-fetoprotéine (afp) et leurs utilisations
US9441002B2 (en) 2012-10-27 2016-09-13 Chemgenes Corporation Dithiolane based thiol modifier for labeling and stronger immobilization of bio-molecules on solid surfaces
JP6494533B2 (ja) 2013-02-28 2019-04-03 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
US20160143914A1 (en) 2013-06-13 2016-05-26 Emory University Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof
KR102325668B1 (ko) 2013-10-23 2021-11-12 켐진스 코포레이션 고체 표면에 생체분자의 강한 고정용 디티올란 기능화된 뉴클레오시드 아미디트 및 지지체
GB201420080D0 (en) * 2014-11-11 2014-12-24 Midatech Ltd And Q Chip Ltd Sustained release encapsulated nanoparticles
CA2988591A1 (fr) 2015-06-30 2017-01-05 Tarveda Therapeutics, Inc. Conjugues cibles, particules et preparations associees
AU2016295602B2 (en) 2015-07-22 2019-11-14 Gnt Biotech & Medicals Corporation PH-sensitive linkers for delivering a therapeutic agent
GB2541166A (en) * 2015-07-24 2017-02-15 Midatech Ltd Nanoparticle-based liver-targeting therapy and imaging
WO2017075495A1 (fr) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Conjugués ciblés sstr, et ses particules et formulations
GB201701745D0 (en) * 2017-02-02 2017-03-22 Midatech Ltd Nanoparticle-based liver-targeting therapy and imaging
CN107096038B (zh) * 2017-04-12 2021-06-18 苏州大学 基于主动反应型一步法的交联纳米药物的制备方法

Also Published As

Publication number Publication date
WO2020109428A1 (fr) 2020-06-04

Similar Documents

Publication Publication Date Title
HK1247614A1 (zh) 治療化合物及其用途
EP3720502A4 (fr) Produits cytobiologiques et leurs utilisations thérapeutiques
IL249370A0 (en) Fap-enabled medical substances and related uses
IL272055A (en) 8,1-naphthyridinone compounds and their uses
HK1248697A1 (zh) 治療化合物及其用途
ZA201802256B (en) Compounds and therapeutic uses thereof
SG11201908281VA (en) Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
IL276753A (en) Epibrotic compounds, their devices and uses
GB201715194D0 (en) Compounds and their therapeutic use
IL265269B (en) New compounds and their medicinal uses
RS60860B1 (sr) Makrogoli za primenu na sluznicu i njihova terapijska upotreba
GB201819430D0 (en) Therapeutic compounds, nanoparticles and uses thereof
GB2579240B (en) New processes, compositions and medical uses
HUE057090T2 (hu) BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében
IL282157A (en) Compounds and their medicinal uses
IL270460B1 (en) New compounds and their medicinal uses
AU2017905204A0 (en) Therapeutic Compounds and Uses Thereof
GB2558788B (en) New therapeutic uses
GB201818517D0 (en) Nanoparticles and uses thereof
GB201707076D0 (en) Novel compounds and therapeutic uses thereof
GB201705678D0 (en) Novel compounds and therapeutic uses thereof
GB201705687D0 (en) Novel compounds and therapeutic uses thereof
GB201705685D0 (en) Novel compounds and therapeutic uses thereof
GB201705682D0 (en) Novel compounds and therapeutic uses thereof
GB201705681D0 (en) Novel compounds and therapeutic uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)